COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03441958
Recruitment Status : Recruiting
First Posted : February 22, 2018
Last Update Posted : August 5, 2019
ExCellThera inc.
Centre de Commercialisation en Immunothérapie du Cancer (C3i)
Information provided by (Responsible Party):
Jean Roy, Ciusss de L'Est de l'Île de Montréal

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 1, 2022
Estimated Study Completion Date : March 1, 2024